SEC Form 4 · accession 0002050172-26-000023
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold Bernstein
Officer — President, R&D & CMO
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 5:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001842295
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2026 | M | 14,853 | $10.42 | A | 14,853 | D | |
| Common StockF2 | Jun 1, 2026 | S | 13,253 | $25.5746 | D | 1,600 | D | |
| Common StockF3 | Jun 1, 2026 | S | 1,600 | $26.3576 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $10.42 | Jun 1, 2026 | M | 14,853 | D | — | Oct 26, 2032 | Common Stock | 14,853 | 207,554 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive.
- F4The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.